Every article, report, and earnings note where LLY appears.
9 articles
Apnimed, Inc. (NASDAQ: APMD) is expected to list on 2026-07-31 in a $14.00 to $16.00 range, offering 10,000,000 shares. The setup is compelling if investors want a late-stage sleep-apnea catalyst, but the deal still hinges on FDA approval and commercial execution.
The latest rotation into energy, utilities, healthcare, and parts of industrials looks less like a healthy handoff from tech and more like a market looking for cover. With semis and software wobbling while oil, defensives, and rate-sensitive groups hold up, this is a stress trade until proven otherwise.
Eli Lilly is still one of the strongest growth stories in large-cap pharma, powered by tirzepatide and an expanding cardiometabolic pipeline. The stock remains constructive, but valuation now demands continued execution rather than multiple expansion.
Eli Lilly's next move looks less like a pipeline trade and more like an access trade. Demand was never the problem; broader PBM coverage and expected Medicare access starting July 1 make the revenue conversion story more immediate.
Healthcare’s leadership over tech and semis looks less like a defensive flinch and more like a valuation message from a still-hawkish market. With rates staying restrictive, investors are rewarding nearer-term earnings durability and demanding a higher bar for crowded long-duration growth.
Eli Lilly and Company (LLY) rises after a positive EU regulatory opinion for Jaypirca in chronic lymphocytic leukemia and fresh analyst support. The move pushed shares to a new high, reinforcing investor confidence in Lilly’s obesity-drug leadership and broader pipeline growth.
Investors still talk about obesity drugs like a category ETF, but the evidence now points to a leadership trade. Eli Lilly is widening the gap with stronger execution, better prescription momentum, and a more threatening pipeline just as Novo Nordisk faces pricing pressure and a weaker growth profile.
Lilly, Novo Nordisk, and Hims & Hers offer three different ways to invest in obesity drugs, with Lilly ranking highest on overall quality and execution.
Eli Lilly and Company (LLY) rises after a strong Q1 2026 beat, a higher full-year outlook, and early launch momentum for its oral GLP-1 obesity pill Foundayo. The rally reflects continued strength in Mounjaro and Zepbound, reinforcing Lilly’s status as a leading growth story in healthcare.
Generate an AI-powered research report — grades, price targets, financials, and chart analysis on demand.
Generate LLY ReportCancel anytime